Transforming Growth Factor Beta Receptor Inhibition Prevents Ventricular Fibrosis In A Mouse Model Of Progressive Cardiac Conduction Disease

Aims Loss-of-function mutations in SCN5A, the gene encoding NaV1.5 channel, have been associated with inherited progressive cardiac conduction disease (PCCD). We have proposed that Scn5a heterozygous knock-out (Scn5a(+/)) mice, which are characterized by ventricular fibrotic remodelling with ageing, represent a model for PCCD. Our objectives were to identify the molecular pathway involved in fibrosis development and prevent its activation.Methods and results Our study shows that myocardial interstitial fibrosis occurred in Scn5a(+/-) mice only after 45 weeks of age. Fibrosis was triggered by transforming growth factor beta (TGF- beta) pathway activation. Younger Scn5a(+/-) mice were characterized by a higher connexin 43 expression than wild-type (WT) mice. After the age of 45 weeks, connexin 43 expression decreased in both WT and Scn5a(+/-) mice, although the decrease was larger in Scn5a(+/-) mice. Chronic inhibition of cardiac sodium current with flecainide (50 mg/kg/day p.o) in WT mice from the age of 6 weeks to the age of 60 weeks did not lead to TGF- beta pathway activation and fibrosis. Chronic inhibition of TGF- beta receptors with GW788388 (5 mg/kg/day p.o.) in Scn5a(+/-) mice from the age of 45 weeks to the age of 60 weeks prevented the occurrence of fibrosis. However, current data could not detect reduction in QRS duration with GW788388.Conclusion Myocardial fibrosis secondary to a loss of Na(V)1.5 is triggered by TGF-beta signalling pathway. Those events are more likely secondary to the decreased Na(V)1.5 sarcolemmal expression rather than the decreased Na+ current per se. TGF-beta receptor inhibition prevents age-dependent development of ventricular fibrosis in Scn5a(+/-) mouse.